GDH Professional Blood Glucose Monitoring System and GDH Professional LED Blood Glucose Monitoring System

K150274 · Infopia Co, Ltd. · NBW · Aug 26, 2015 · Clinical Chemistry

Device Facts

Record IDK150274
Device NameGDH Professional Blood Glucose Monitoring System and GDH Professional LED Blood Glucose Monitoring System
ApplicantInfopia Co, Ltd.
Product CodeNBW · Clinical Chemistry
Decision DateAug 26, 2015
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 862.1345
Device ClassClass 2
AttributesPediatric

Intended Use

The GDH Professional Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in capillary whole blood from the fingertips, ventral palm, dorsal hand, upper arm, forearm, calf and thigh, and venous whole blood. The GDH Professional Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of diabetes control program. This system should only be used with auto-disabling, single-use lancing devices. The GDH Professional Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes and/or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly). The GDH Professional test strips are for use with the GDH Professional meter to quantitatively measure glucose (sugar) in venous whole blood samples and fresh capillary whole blood samples drawn from the fingertips, ventral palm, dorsal hand, upper arm, forearm, calf and/or thigh. The GDH Professional control solutions are for use with the GDH Professional meter and GDH Professional test strips to check that the meter and test strips are working together properly and that the test is performing correctly.

Device Story

System measures glucose concentration in capillary/venous whole blood; utilizes test strips and meter. Principle of operation: electrical current generated in test strip proportional to glucose concentration; current measured by meter. Used in professional healthcare settings for multiple-patient monitoring; operated by healthcare professionals. Output: quantitative glucose value displayed on meter screen. Benefits: aids in monitoring diabetes control programs. Modifications from predicate include meter appearance, battery quantity, LCD display, and LED light indicator (for LED model).

Clinical Evidence

Bench testing only. Verification and validation activities confirmed performance, functionality, and reliability. Disinfection study validated CaviWipes (EPA #46781-8) for inactivation of live virus. Robustness study simulated 3 years of cleaning/disinfection cycles, confirming maintenance of appearance, operational functions, and analytical performance.

Technological Characteristics

In vitro diagnostic glucose test system. Electrochemical sensing principle. Components: meter, test strips, control solutions. Features: LED display/indicator, battery-powered. Professional use environment. Validated for disinfection with CaviWipes.

Indications for Use

Indicated for quantitative glucose measurement in capillary and venous whole blood in professional healthcare settings to monitor diabetes control programs. Not for neonatal use, diabetes diagnosis, or screening. Alternative site testing restricted to steady-state glucose conditions.

Regulatory Classification

Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0} SPECIAL 510(k): Device Modification OIR Review Memorandum To: THE FILE RE: DOCUMENT NUMBER K150274 This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable (delete/add items as necessary): 1. The name and 510(k) number of the SUBMITTER'S previously cleared device. K132966, GluNEO Lite Professional Blood Glucose Monitoring System. 2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use). 3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed. This change was for: A. Change of the system names from GluNEO Lite Professional Blood Glucose Monitoring System to GDH Professional Blood Glucose Monitoring System and GDH Professional LED Blood Glucose Monitoring System. B. Change in the names of control solutions from GluNEO Lite Professional Control Solutions to GDH Professional Control Solutions. C. Change in battery number from one to two batteries. D. Change in the display type from a positive LCD screen to a negative LCD screen with backlighting for the GDH Professional LED Blood Glucose Monitoring System. E. Change in the physical appearance including color, size and weight. F. Changes to the appearance of before meal and after meal icons, and to the location of these and other icons on the display screen. G. Inclusion of an LED light for illumination of the sample test port (GDH Professional LED Blood Glucose Monitoring System models only). 4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, physical characteristics (dimensions, weight), and specifications were provided. 5. A Design Control Activities Summary which includes: a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device. {1} Page 2 of 2 The GDH Professional Blood Glucose Monitoring System and GDH Professional LED Professional Blood Glucose Monitoring System are intended for multiple-patient use. The materials of the meter for each device are identical apart from an additional LED light on the GDH Professional LED Professional Blood Glucose Monitoring System. Disinfection efficacy studies were performed on the materials comprising the GDH Professional and GDH Professional LED Blood Glucose meter by an outside commercial testing laboratory demonstrating complete inactivation of hepatitis B virus (HBV) with the chosen disinfectant, CaviWipes (EPA Registration # 46781-8). Robustness studies were also performed by the sponsor demonstrating that there was no change in performance or external materials of the meter after 10,950 cleaning and disinfection cycles with the CaviWipes wipes. The robustness studies were designed to simulate 3 years of multiple-patient use. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures.
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...